Stock DNA
Medical Specialties
USD 53 Million (Micro Cap)
NA (Loss Making)
NA
99.16%
-1.01
-192.33%
1.18
Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Sep 2023)
Net Profit:
-17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.77%
0%
-0.77%
6 Months
-16.29%
0%
-16.29%
1 Year
-66.14%
0%
-66.14%
2 Years
-97.33%
0%
-97.33%
3 Years
-99.81%
0%
-99.81%
4 Years
-62.19%
0%
-62.19%
5 Years
-62.19%
0%
-62.19%
Eargo, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.98%
EBIT Growth (5y)
-174.96%
EBIT to Interest (avg)
-86.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.44
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.71%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.18
EV to EBIT
-0.09
EV to EBITDA
-0.10
EV to Capital Employed
-7.96
EV to Sales
0.19
PEG Ratio
NA
Dividend Yield
99.16%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-192.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 18 Schemes (1.55%)
Foreign Institutions
Held by 25 Foreign Institutions (2.09%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ
Sep'23
Jun'23
Change(%)
Net Sales
8.30
8.10
2.47%
Operating Profit (PBDIT) excl Other Income
-15.90
-24.30
34.57%
Interest
0.00
0.00
Exceptional Items
-0.90
0.00
Consolidate Net Profit
-17.30
-25.20
31.35%
Operating Profit Margin (Excl OI)
-2,064.70%
-3,182.80%
111.81%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2023 is 2.47% vs -31.36% in Jun 2023
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2023 is 31.35% vs -15.07% in Jun 2023
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
37.20
32.10
15.89%
Operating Profit (PBDIT) excl Other Income
-105.30
-151.10
30.31%
Interest
0.50
1.10
-54.55%
Exceptional Items
-46.30
0.00
Consolidate Net Profit
-157.50
-157.80
0.19%
Operating Profit Margin (Excl OI)
-3,000.40%
-4,878.50%
187.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 15.89% vs -53.61% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is 0.19% vs -426.00% in Dec 2021
About Eargo, Inc. 
Eargo, Inc.
Medical Specialties
Eargo, Inc. is a medical device company that provides Eargo solution to create a hearing aid. The Company’s in-the-canal devices feature audio, are designed to provide up to 16 hours of battery life and have Flexi Fibers or Flexi Palms, which are designed to enable the unit to float in the ear canal, allowing air and sound to pass freely around them. In addition, Eargo hearing aids allows its users to cycle through four sound profiles, which includes features, such as amplification and noise levels, while on-the-go to accommodate different ambient noise environments. It offers three versions of its hearing aids, the Eargo Max, the Eargo Neo and the Eargo Neo HiFi. Its Eargo Neo and Eargo Neo HiFi offers a companion mobile app that allows customers to control their device and personalize their sound profiles. When paired with the charging case, customers can also wirelessly receive personalized sound settings based on their usage and preferences directly from its hearing professionals.
Company Coordinates 
Company Details
1600 Technology Drive, 6Th Floor , SAN JOSE CA : 95110
Registrar Details






